<p>PMV Pharmaceuticals, Inc. (PMVP) 发布了其第三季度财报。以下是 PMV Pharmaceuticals, Inc. 向投资者提供的信息概述。</p>
<h3>认识你的 ETF AI 分析师</h3>
<ul>
<li>了解 TipRanks 的 <em>ETF</em> AI 分析师如何帮助你做出更明智的投资决策</li>
<li>探索 TipRanks 用户喜爱的 ETF，并查看 <strong><em>ETF</em> AI 分析师</strong> 对你关注的 ETF 的见解。</li>
</ul>
<p>PMV Pharmaceuticals, Inc. 是一家精准肿瘤学公司，专注于开发针对 p53 突变的小分子疗法，总部位于新泽西州普林斯顿。在截至 2025 年 9 月 30 日的最新财报中，PMV Pharmaceuticals 报告净亏损为 2110 万美元，而去年同期的净亏损为 1920 万美元。公司的总运营费用增加至 2250 万美元，主要由于研发成本上升。尽管亏损，PMV Pharmaceuticals 仍保持强劲的现金状况，现金、现金等价物和可交易证券总额为 1.293 亿美元，为持续运营提供了资金保障。展望未来，PMV Pharmaceuticals 计划专注于推动其产品候选者通过临床试验，管理层对其战略计划和财务状况充满信心，以支持持续的研发活动。</p>

PMVP

<p>PMV Pharmaceuticals, Inc. 报告第三季度净亏损为 2110 万美元，较去年同期的 1920 万美元有所增加。由于研发成本增加，运营费用上升至 2250 万美元。尽管出现亏损，公司仍持有 1.293 亿美元的现金及现金等价物，确保运营的持续性。PMV 计划通过临床试验推进其产品候选者，管理层对其战略和财务状况在持续研发活动中的信心十足</p>

<p>Pmv Pharmaceuticals, Inc. ( (PMVP) ) has released its Q3 earnings. Here is a breakdown of the information Pmv Pharmaceuticals, Inc. presented to its investors.</p>
<div class="lb-trans"><p>PMV Pharmaceuticals, Inc. (PMVP) 发布了其第三季度财报。以下是 PMV Pharmaceuticals, Inc. 向投资者提供的信息概述。</p>
</div><h3>Meet Your ETF AI Analyst</h3>
<div class="lb-trans"><h3>认识你的 ETF AI 分析师</h3>
</div><ul>
<li>Discover how TipRanks' <em>ETF</em> AI Analyst can help you make smarter investment decisions</li>
<li>Explore ETFs TipRanks' users love and see what insights the <strong><em>ETF</em> AI Analyst</strong> reveals about the ones you follow.</li>
</ul>
<div class="lb-trans"><ul>
<li>了解 TipRanks 的 <em>ETF</em> AI 分析师如何帮助你做出更明智的投资决策</li>
<li>探索 TipRanks 用户喜爱的 ETF，并查看 <strong><em>ETF</em> AI 分析师</strong> 对你关注的 ETF 的见解。</li>
</ul>
</div><p>PMV Pharmaceuticals, Inc. is a precision oncology company focused on developing small molecule therapies targeting p53 mutations, headquartered in Princeton, New Jersey. In its latest earnings report for the quarter ended September 30, 2025, PMV Pharmaceuticals reported a net loss of $21.1 million, compared to a net loss of $19.2 million in the same period last year. The company’s total operating expenses increased to $22.5 million, driven by higher research and development costs. Despite the losses, PMV Pharmaceuticals maintains a strong cash position with $129.3 million in cash, cash equivalents, and marketable securities, providing a runway for continued operations. Looking ahead, PMV Pharmaceuticals plans to focus on advancing its product candidates through clinical trials, with the management expressing confidence in their strategic plans and financial position to support ongoing research and development activities.</p>
<div class="lb-trans"><p>PMV Pharmaceuticals, Inc. 是一家精准肿瘤学公司，专注于开发针对 p53 突变的小分子疗法，总部位于新泽西州普林斯顿。在截至 2025 年 9 月 30 日的最新财报中，PMV Pharmaceuticals 报告净亏损为 2110 万美元，而去年同期的净亏损为 1920 万美元。公司的总运营费用增加至 2250 万美元，主要由于研发成本上升。尽管亏损，PMV Pharmaceuticals 仍保持强劲的现金状况，现金、现金等价物和可交易证券总额为 1.293 亿美元，为持续运营提供了资金保障。展望未来，PMV Pharmaceuticals 计划专注于推动其产品候选者通过临床试验，管理层对其战略计划和财务状况充满信心，以支持持续的研发活动。</p>
</div>

PMV Pharmaceuticals 报告季度亏损扩大